Premium
β‐ADRENOCEPTOR AGONISTS ENHANCE 5‐HYDROXYTRYPTAMINE‐MEDIATED BEHAVIOURAL RESPONSES
Author(s) -
COWEN P.J.,
GRAHAMESMITH D.G.,
GREEN A.R.,
HEAL D.J.
Publication year - 1982
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/j.1476-5381.1982.tb09216.x
Subject(s) - quipazine , clenbuterol , salbutamol , terbutaline , agonist , antagonist , pharmacology , chemistry , endocrinology , medicine , atenolol , methamphetamine , tranylcypromine , serotonin , serotonergic , receptor , monoamine oxidase , biochemistry , blood pressure , enzyme , asthma
1 The β‐adrenoceptor agonists, salbutamol, terbutaline and clenbuterol, were investigated for their effect on 5‐hydroxytryptamine‐mediated (5‐HT) hyperactivity. 2 The lipophilic β‐adrenoceptor agonist, clenbuterol (5 mg/kg) enhanced the behaviours induced by quipazine (25 mg/kg), including headweaving, forepaw treading and hind‐limb abduction and thus increased automated activity recording. Clenbuterol (5 mg/kg) also enhanced the hyperactivity syndrome produced by the 5‐HT agonist, 5‐methoxy N,N ‐dimethyltryptamine (2 mg/kg) and the combination of tranylcypromine (10 mg/kg) and L‐tryptophan (50 mg/kg). Salbutamol and terbutaline potentiated quipazine‐induced hyperactivity only when given at the higher dose of 20 mg/kg. 3 The effect of clenbuterol in enhancing quipazine hyperactivity was blocked by the centrally acting β 1 ‐adrenoceptor antagonist, metoprolol (5 mg/kg), but not by the β 2 ‐adrenoceptor antagonist, butoxamine (5 mg/kg) or the peripherally acting β 1 ‐adrenoceptor antagonist, atenolol (5 mg/kg). 4 Clenbuterol (5 mg/kg) did not enhance the circling responses produced by methamphetamine (0.5 mg/kg) in unilateral nigrostriatal‐lesioned rats. 5 The results suggest that β‐adrenoceptor agonists in common with some established antidepressant treatments produce enhancement of 5‐HT‐mediated behavioural responses.